Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In the Phase 2 clinical study, rapid and faster improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo (half normal saline), together with decreases in pro-inflammatory cytokines.
Lead Product(s): BIO-11006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO-11006
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
Data to be presented showed that inhaled BIO-11006 decreases metastasis and tumor progression, and increases the overall response rate and survival in patients with advanced NSCLC.
Lead Product(s): BIO-11006
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020